ASHP therapeutic position statement on the use of second-generation antipsychotic medications in the treatment of adults with psychotic disorders

American Journal of Health-System Pharmacy

Volumn 64, Issue 8, 2007, Pages 863-876

  Noel, Jason M ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b Rosewood Center   (United States)

Author keywords

American Society of Health System Pharmacists; Antipsychotic agents; Compliance; Costs; Drug use; Mechanism of action; Organizations; Patients; Protocols; Psychotic disorders; Toxicity

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZATROPINE; CHLORPROMAZINE; CLOZAPINE; CYTOCHROME P450 INHIBITOR; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR BLOCKING AGENT; DROPERIDOL; FLUPHENAZINE; GLUTAMIC ACID; HALOPERIDOL; INVEGA; LOXAPINE; MESORIDAZINE; MOLINDONE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PERPHENAZINE; PIMOZIDE; PLACEBO; QUETIAPINE; RISPERIDONE; SEROTONIN 2 ANTAGONIST; SEROTONIN 2 RECEPTOR; THIORIDAZINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZIPRASIDONE;

AGRANULOCYTOSIS; AKATHISIA; ANXIETY; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; DRUG INDICATION; DRUG RESEARCH; DRUG WITHDRAWAL; DYSTONIA; EXTRAPYRAMIDAL SYNDROME; GLUCOSE BLOOD LEVEL; HEMATOLOGIC DISEASE; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; MEDICAL SOCIETY; METABOLIC DISORDER; MOTOR DYSFUNCTION; MYOCARDITIS; NEGATIVE SYNDROME; PARKINSONISM; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PSYCHOSIS; QT PROLONGATION; RESPIRATION DEPRESSION; RESTLESSNESS; REVIEW; SEIZURE; SIDE EFFECT; STROKE; SUDDEN DEATH; SUICIDE; TARDIVE DYSKINESIA; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT CHANGE; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 34247197617     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp060343     Document Type: Review

References (119)

1. Schizophrenia and other psychotic disorders. In: American Psychiatric Association. DSM-IV-TR: diagnostic and statistical manual of mental disorders, 4th ed., text revision. Washington, DC: American Psychiatric Press; 2000.
2. Keith SJ, Regier DA, Rae DS. Schizophrenic disorders. In: Robins LN, Regier DA, eds. Psychiatric disorders in America: the Epidemiologic Catchment Area Study. New York: Free Press; 1991: 33-52.
3. Kessler RC, McGonagle KA, Zhao S et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry. 1994; 52:8-19.
4. Loranger AW. Sex differences in age at onset of schizophrenia. Arch Gen Psychiatry. 1984; 41:157-61.
5. Hafner H, Maurer K, Loeffler W et al. The influence of age and sex on the onset and early course of schizophrenia. Br J Psychiatry. 1993; 162:80-6.
6. Kim JS, Kornhuber HH, Schmid-Burgk W et al. Low cerebrospinal fluid glutamate in schizophrenia patients and a new hypothesis on schizophrenia. Neurosci Lett. 1980; 20:379-82.
7. Krystal JH, Karper LP, Seibyl JP et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry. 1994; 51:199-214.
8. Hughes JR, Hatsukami DK, Mitchell JE et al. Prevalence of smoking among psychiatric outpatients. Am J Psychiatry. 1986; 143:993-7.
9. Dalack GW, Healy DJ, Meador-Woodruff JH. Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings. Am J Psychiatry. 1998; 155:1490-501.
10. Stahl SM. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part I: "Goldilocks" actions at dopamine receptors. J Clin Psychiatry. 2001; 62:841-2.
11. Stahl SM. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part II: illustrating their mechanism of action. J Clin Psychiatry. 2001; 62:923-4.
12. Kapur S, Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry. 1996; 153:466-76.
13. Kane J, Honigfeld G, Singer J et al. Clozapine for the treatment-resistant schizophrenic, a double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988; 45:789-96.
14. Breier A, Buchanan RW, Kirkpatrick. B et al. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry. 1994; 152:20-6.
15. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry. 1994; 151:825-35.
16. Chouinard G, Jones B, Remington G et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol. 1993; 13:25-40.
17. Kane JM, Eerdekens M, Lindenmayer JP et al. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry. 2003; 160:1125-32.
18. Beasley CM, Tollfeson G, Tran P et al. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology. 1996; 14:111-23.
19. Beasley CM, Sanger T, Satterlee W et al. Olanzapine vs placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology. 1996; 124:159-67.
20. Arvanitis LA, Miller BG. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry. 1997; 42:233-46.
21. Small JG, Hirsch SR, Arvanitis LA et al. Quetiapine in patients with schizophrenia: a high- and low-dose double-blind comparison with placebo. Arch Gen Psychiatry. 1997; 54:549-57.
22. Daniel DG, Zimbroff DL, Potkin SG et al. Ziprasidone 80 mg/day and 160 mg/ day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Neuropsychopharmacology. 1999; 20:491-505.
23. Keck P Jr, Buffenstein A, Ferguson J et al. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology. 1998; 140:173-84.
24. Kane JM, Carson WH, Saha AR et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2002; 63:763-71.
25. Lieberman JA, Stroup TS, McEvoy JP et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005; 353:1209-23.
26. Sharma T, Antonova L. Cognitive function in schizophrenia: deficits, functional consequences, and future treatment. Psychiatr Clin North Am. 2003; 26:25-40.
27. Green MF. What are the functional consequences of neurocognitive deficits of schizophrenia? Am J Psychiatry. 1996; 153:321-30.
28. Liddle PF. Cognitive impairment in schizophrenia: its impact on social functioning. Acta Psychiatr Scand Suppl. 2000; 400:11-6.
29. Spohn HE, Strauss ME. Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia. J Abnorm Psychol. 1989; 98:367-80.
30. Bilder RM, Goldman RS, Volavka J et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry. 2002; 159:1018-28.
31. Hagger C, Buckley P, Kenny JT et al. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol Psychiatry. 1993; 34:702-12.
32. Grace J, Bellus SB, Raulin ML et al. Long-term impact of clozapine and psychosocial treatment on psychiatric symptoms and cognitive functioning. Psychiatr Serv. 1996; 47:41-5.
33. Buchanan RW, Holstein C, Breier A. The comparative efficacy and long-term effect of clozapine on neuropsychological test performance. Biol Psychiatry. 1994; 36:717-25.
34. Cornblatt B, Kern RS, Carson WH et al. Neurocognitive effects of aripiprazole versus olanzapine in stable psychosis. Presented at 23rd Collegium Internationale Neuropsychopharmacologicum Congress. Montreal, Canada; 2002 Jun.
35. Stahl SM. "Hit-and-run" actions at dopamine receptors, part 1: mechanism of action of second-generation antipsychotics. J Clin Psychiatry. 2001; 62:670-1.
36. Leucht S, Pitschel-Walz G, Abraham D et al. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials. Schizophr Res. 1999; 35:51-68.
37. Tollefson GD, Beasley CM, Tamura RN et al. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am J Psychiatry. 1997; 154:1248-54.
38. Jeste DV, Lacro JP, Bailey A et al. Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients. J Am Geriatr Soc. 1999; 47:716-9.
39. Jeste DV, Okamoto A, Napolitano J et al. Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. Am J Psychiatry. 2000; 157:1150-5.
40. Beasley CM, Dellva MA, Tamura RN et al. Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol. Br J Psychiatry. 1999; 174:23-30.
41. Farah A. Reduction of tardive dyskinesia with quetiapine. Schizophr Res. 2001; 47:309-10. Letter.
42. Povlssen UJ, Noring U, Fog R et al. Tolerability and therapeutic effect of clozapine: a retrospective investigation of 216 patients treated with clozapine for up to 12 years. Acta Psychiatr Scand. 1985; 71:176-85.
43. Kurz M, Hummer M, Oberbauer H et al. Extrapyramidal side effects of clozapine and haloperidol. Psychopharmacology. 1995; 118:52-6.
44. Casey DE. Clozapine: neuroleptic - induced EPS and tardive dyskinesia. Psychopharmacology. 1989; 99:S47-53.
45. Lieberman JA, Saltz BL, Johns CA et al. The effects of clozapine on tardive dyskinesia. Br J Psychiatry. 1991; 158:503-10.
46. Spivak B, Mester R, Abesgaus J et al. Clozapine treatment for neuroleptic-induced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients. J Clin Psychiatry. 1997; 58:318-22.
47. Tamminga CA, Thaker GK, Moran M et al. Clozapine in tardive dyskinesia: observations from human and animal model studies. J Clin Psychiatry. 1994; 55(suppl B):102-6.
48. Ahmed S, Chengappa KN, Naidu VR et al. Clozapine withdrawal-emergent dystonias and dyskinesias: a case series. J Clin Psychiatry. 1998; 59:472-7.
49. Dickson RA, Seeman MV, Corenblum B. Hormonal side effects in women: typical versus second-generation antipsychotic treatment. J Clin Psychiatry. 2000; 61(suppl 3):10-5.
50. Windgassen K, Wesselman U, Schulze-Monking H. Galactorrhea and hyperprolactinemia in schizophrenic patients on neuroleptics: frequency and etiology. Neuropsychobiology. 1996; 33:142-6.
51. Arana GW. An overview of side effects caused by typical antipsychotics. J Clin Psychiatry. 2000; 61(suppl 8):5-11.
52. Petty RG. Prolactin and antipsychotic medications: mechanisms of action. Schizophr Res. 1999; 35(suppl):S67-73.
53. Volavka J, Czobor P, Cooper TB et al. Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. J Clin Psychiatry. 2004; 65:57-61.
54. Breier AF, Malhotra AK, Su T et al. Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response. Am J Psychiatry. 1999; 156:294-8.
55. Crawford AM, Beasley CM, Tollefson GD. The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophr Res. 1997; 26:41-54.
56. David SR, Taylor CC, Kinon BJ et al. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin Ther. 2000; 22:1085-96.
57. Bunker MT, Marken PA, Schneiderhan ME et al. Attenuation of antipsychotic-induced hyperprolactinemia with clozapine. J Child Adolesc Psychopharmacol. 1997; 7:65-9.
58. Allison DB, Fontaine KR, Heo M et al. The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry. 1999; 60:215-20.
59. Mukherjee S, Decina P, Bocola V et al. Diabetes mellitus in schizophrenic patients. Compr Psychiatry. 1996; 37:68-73.
60. Brambilla F, Guastalla A, Guerrini A et al. Glucose-insulin metabolism in chronic schizophrenia. Dis Nerv Syst. 1976; 37:98-103.
61. Tsuang MT, Perkins K, Simpson JC. Physical diseases in schizophrenia and affective disorder. J Clin Psychiatry. 1983; 44:42-6.
62. Borovicka MC, Fuller MA, Konicki PE et al. Phenylpropanolamine appears not to promote weight loss in patients with schizophrenia who have gained weight during clozapine treatment. J Clin Psychiatry. 2002; 63:345-8.
63. Ball MP, Coons VB, Buchanan RW. A program for treating olanzapine-related weight gain. Psychiatr Serv. 2001; 52:967-9.
64. Green AI, Patel JK, Goisman RM et al. Weight gain from novel antipsychotic drugs: need for action. Gen Hosp Psychiatry. 2000; 22:224-35.
65. Doss FW. The effect of antipsychotic drugs on body weight: a retrospective review. J Clin Psychiatry. 1979; 40:528-30.
66. Parent MM, Roy S, Sramek J et al. Effect of molindone on weight change in hospitalized schizophrenic patients. Drug Intell Clin Pharm. 1986; 20:873-5.
67. Gardos G, Cole JO. Weight reduction in schizophrenics by molindone. Am J Psychiatry. 1977; 134:302-4.
68. Allison DB, Mentore JL, Heo M et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999; 156:1686-96.
69. Henderson DC, Cagliero E, Gray C et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry. 2000; 157:975-81.
70. Beasley CM, Tollefson GD, Tran PV. Safety of olanzapine. J Clin Psychiatry. 1997; 58(suppl 10):13-7,19-21.
71. Muench J, Carey M. Diabetes mellitus associated with second-generation antipsychotic medications: new case report and review of the literature. J Am Board Fam Pract. 2001; 14:278-82.
72. Jin H, Meyer JM, Jeste DV. Phenomenology of and risk factors for new onset diabetes mellitus associated with second-generation antipsychotics: an analysis of 45 published cases. Ann Clin Psychiatry. 2002; 14:59-64.
73. Koller EA, Cross JT, Doraiswamy PM et al. Risperidone-associated diabetes mellitus: a pharmacovigilance study. Pharmacotherapy. 2003; 23:735-44.
74. Sernyak MJ, Leslie DL, Alarcon RD. Association of diabetes mellitus with use of second-generation neuroleptics in the treatment of schizophrenia. Am J Psychiatry. 2002; 159:561-6.
75. Newcomer JW, Haupt DW, Fucetola R. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry. 2002; 59:337-45.
76. Meyer JM. Novel antipsychotics and severe hyperlipidemia. J Clin Psychopharm. 2001; 21:369-74.
77. Meyer JM. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. J Clin Psychiatry. 2002; 63:425-33.
78. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists et al. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004; 27:596-601.
79. Mehtonen OP, Aranko K, Malkonen L et al. A survey of sudden death associated with the use of antipsychotic or antidepressant drugs: 49 cases in Finland. Acta Psychiatr Scand. 1991; 84:58-64.
80. Reilly JG, Ayis SA, Ferrier IN et al. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet. 2000; 355:1048-52.
81. Food and Drug Administration. Briefing document for Zeldox capsules (ziprasidone HCl). www.fda.gov/ohrms/ dockets/ac/00/backgrd/3619b1a.pdf (accessed 2007 Jan 16).
82. Geodon (ziprasidone hydrochloride) prescribing information. New York: Pfizer Inc.; 2006 Nov.
83. Merrill DB, Dec GW, Goff DC. Adverse cardiac effects associated with clozapine. J Clin Psychopharmacol. 2005; 25:32-41.
84. La Grenade L, Graham D, Trontell A. Myocarditis and cardiomyopathy associated with clozapine use in the United States. N Engl J Med. 2001; 345:224-5.
85. Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA. 2005; 293:596-608.
86. Herrmann N, Lanctot KL. Do atypical antipsychotics cause stroke? CNS Drugs. 2005; 19:91-103.
87. Lieberman JA, Johns CA, Kane JM et al. Clozapine-induced agranulocytosis: non-cross-reactivity with other psychotropic drugs. J Clin Psychiatry. 1988; 49:271-7.
88. Alvir JJ, Lieberman JA, Safferman AZ et al. Clozapine-induced agranulocytosis - incidence and risk factors in the United States. N Engl J Med. 1993; 329: 162-7.
89. Honigfeld G, Arellano F, Sethi J et al. Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. J Clin Psychiatry. 1998; 59(suppl 3):3-7.
90. Munro J, O'Sullivan D, Andrews C et al. Active monitoring of 12,760 clozapine recipients in the UK and Ireland: beyond pharmacovigilance. Br J Psychiatry. 1999; 175:576-80.
91. Silvestri RC, Bromfield EB, Khoshbin S. Clozapine-induced seizures and EEG abnormalities in ambulatory psychiatric patients. Ann Pharmacother. 1998; 32:1147-51.
92. Sprague DA, Loewen PS, Raymond CB. Selection of atypical antipsychotics for the management of schizophrenia. Ann Pharmacother. 2004; 38:313-9.
93. Love RC, Conley RR, Kelly DL et al. A dose-outcome analysis of risperidone. J Clin Psychiatry. 1999; 60:771-5.
94. Moller HJ, Bauml J, Ferrero F et al. Risperidone in the treatment of schizophrenia: results of a study of patients from Germany, Austria and Switzerland. Eur Arch Psychiatry Clin Neurosci. 1997; 246:291-6.
95. Philipo M. Neuroleptic treatment long term: results with risperidone. Presented at 21st Collegium Internationale NeuroPsychopharmacologicum Congress. Glasgow, Scotland; 1998 Jul.
96. Sajatovic M, Ramirez LF, Belton J et al. Health resource utilization and risperidone therapy in patients with serious mental illness. Presented at 21st Collegium Internationale Neuro-Psychopharmacologicum Congress. Glasgow, Scotland; 1998 Jul.
97. Volavka J, Czobor P, Sheitman B et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry. 2002; 159:255-62.
98. Miller AL, Hall CS, Buchanan RW et al. The Texas medication algorithm project - antipsychotic algorithm for schizophrenia: 2003 update. J Clin Psychiatry. 2004; 65:500-8.
99. Lehman AF, Lieberman JA, Dixon LB et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004; 161(2 suppl):1-56.
100. Lehman AF, Steinwachs DM. Translating research into practice: the schizophrenia patient outcomes research team (PORT) treatment recommendations. Schizophr Bull. 1998; 24:1-10.
101. Stahl SM. Antipsychotic polypharmacy: squandering precious resources? J Clin Psychiatry. 2002; 63:93-4.
102. Casey DE, Saha AR, Ali MW et al. Switching to aripiprazole monotherapy. Presented at 23rd Collegium Internationale Neuropsycholpharmacologicum Congress. Montreal, Canada. 2002 Jun.
103. Marder SR, Essock SM, Miller AL et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry. 2004; 161:1334-49.
104. Perry PJ, Miller DD, Arndt SV et al. Clozapine and norclozapine plasma concentrations and clinical response of treatment refractory schizophrenic patients. Am J Psychiatry. 1991; 148:231-5.
105. Kronig MH, Munne RA, Szymanski S et al. Plasma clozapine levels and clinical response for treatment refractory schizophrenic patients. Am J Psychiatry. 1995; 152:179-82.
106. Gaertner I, Gaertner HJ, Vonthein R et al. Therapeutic drug monitoring of clozapine in relapse prevention: a five-year prospective study. J Clin Psychopharmacol. 2001; 21:305-10.
107. Rabinowitz J, Lichtenberg P, Kaplan Z et al. Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics. Am J Psychiatry. 2001; 158:266-9.
108. Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med. 2002; 346:16-22.
109. Barbui C, Lintas C, Percudani M. Head-to-head comparison of the costs of atypical antipsychotics: a systematic review. CNS Drugs. 2005; 19:935-50.
110. Mladsi DM, Grogg AL, Irish WD et al. Pharmacy cost evaluation of risperidone, olanzapine, and quetiapine for the treatment of schizophrenia in acute care inpatient settings. Curr Med Res Opin. 2004; 20:1883-93.
111. Coley KC, Carter CS, DaPos SV et al. Effectiveness of antipsychotic therapy in a naturalistic setting: a comparison between risperidone, perphenazine, and haloperidol. J Clin Psychiatry. 1999; 60:850-6.
112. Rosenheck R, Cramer J, Allan E et al. Cost-effectiveness of clozapine in patients with high and low levels of hospital use. Arch Gen Psychiatry. 1999; 56:565-72.
113. Chouinard G, Albright PS. Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol. J Clin Psychopharmacol. 1997; 17:298-307.
114. Franz M, Lis S, Pluddemann K et al. Conventional versus second-generation neuroleptics: subjective quality of life in schizophrenic patients. Br J Psychiatry. 1997; 170:422-5.
115. Roy A. Depression, attempted suicide, and suicide in patients with chronic schizophrenia. Psychiatr Clin North Am. 1986; 9:193-206.
116. Radomsky ED, Haas GL, Mann JJ et al. Suicidal behavior in patients with schizophrenia and other psychotic disorders. Am J Psychiatry. 1999; 156:1590-5.
117. Cohen LJ, Test MA, Brown RL. Suicide and schizophrenia: data from a prospective community treatment study. Am J Psychiatry. 1990; 147:602-7.
118. Meltzer HY, Okayli G. Reduction of suicidally during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry. 1995; 152:183-90.
119. Meltzer HY, Alphs L, Green AI et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSEPT). Arch Gen Psychiatry. 2003; 60:82-91.